PRLD News and Press, Prelude Therapeutics Incorporated From 06/02/23

2023-06-02 17:54:17 ET Summary Today, we take our first look at a small developmental company called Prelude Therapeutics that finds itself deep in Busted IPO Territory. The company came public to raise proceeds to focus on develop small molecule therapies for solid tumors, select...

WILMINGTON, Del., May 31, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in the Jefferies Healthcare Conference, taking place in New York City, June 7 to 9, 202...

WILMINGTON, Del., May 18, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated ("Prelude" or the "Company") (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the pricing of its underwritten public offering of 3,048,522 shares of its voting common stock and 1,448,2...

2023-05-17 16:36:10 ET Prelude Therapeutics ( NASDAQ: PRLD ) on Wednesday said it was launching a public offering of common stock and pre-funded warrants of up to $100M. PRLD stock slipped 4.8% to $6 after hours. All of the shares of common stock and pre-funded warrant...

2023-05-08 08:43:57 ET Prelude Therapeutics press release ( NASDAQ: PRLD ): Q1 GAAP EPS of -$0.58 beats by $0.10 . Cash, cash equivalents, and marketable securities as of March 31, 2023, were $172.3 million. Prelude anticipates that its existing cash, cash equivalents ...

Eight abstracts presented at AACR 2023 demonstrate progress of the pipeline Cash runway unchanged, supporting operations into the fourth quarter of 2024 WILMINGTON, Del., May 08, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision ...

WILMINGTON, Del., April 27, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will participate in three upcoming healthcare investment conferences. Details are as follows: ...

WILMINGTON, Del., April 11, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced details relating to eight abstracts being presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, t...

Four differentiated clinical compounds progressing through Phase 1 towards key data milestones Eight abstracts accepted for presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting Cash balance of $201.7 million as of December 31, 2022; runway rema...

WILMINGTON, Del., March 15, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced a clinical trial collaboration with BeiGene, for future evaluation of its investigational CDK9 inhibitor, PRT2527, in c...